Texas Instruments and Other Overlooked Dividend Aristocrat Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2024
0mins
Source: Barron's
Dividend Growth Indices: The S&P 500 Dividend Aristocrats Index and the S&P High Yield Dividend Aristocrats Index provide reliable options for income-seeking investors, with the latter including a broader range of small- and mid-cap stocks that have increased dividends for at least 20 years.
Investment Considerations: While smaller-cap dividend-paying companies can offer attractive growth potential, investors should be cautious due to variability in earnings and potential debt issues; ETFs like SPDR S&P Dividend (SDY) and ProShares Russell 2000 Dividend Growers (SMDV) are suggested for exposure to these stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 238.330
Low
190.00
Averages
218.50
High
240.00
Current: 238.330
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TALVEY and DARZALEX Combination Therapy Significantly Improves Outcomes in Multiple Myeloma Patients
- Clinical Trial Results: Johnson & Johnson's MonumenTAL-3 study demonstrates that the combination of TALVEY and DARZALEX significantly reduces the risk of disease progression or death by 72% in patients with relapsed/refractory multiple myeloma, highlighting the efficacy of this regimen.
- Survival Rate Improvement: At 24 months, the progression-free survival rate for the TALVEY and DARZALEX combination reaches 81.3%, compared to only 51.2% for standard treatment, indicating the potential of this new therapy in earlier lines of treatment.
- Safety Analysis: While the side effects of the TALVEY and DARZALEX combination align with the known safety profiles of each monotherapy, the Tal-DP group shows a significantly lower risk of severe infections compared to standard treatment, indicating better tolerability.
- Market Outlook: Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for the TALVEY and DARZALEX combination therapy, which is expected to accelerate the market introduction of this treatment and further solidify its leadership position in the multiple myeloma treatment landscape.
See More
Johnson & Johnson Acquires Firefly Bio to Boost Cancer Drug Development
- Oncology Market Potential: Precedence Research indicates that the global oncology market is currently valued at nearly $280 billion and is projected to reach $700 billion by 2035, presenting significant growth opportunities for Johnson & Johnson.
- Acquisition Strategy: Johnson & Johnson's recent $1 billion acquisition of Firefly Bio aims to leverage its unique Firelink degrader antibody conjugate platform, focusing on treating KRAS tumors, thereby enhancing its competitive edge in cancer therapeutics.
- Technological Innovation: The Firelink platform enhances the efficacy of antibody-drug conjugates by targeting specific proteins on tumor cells, which is expected to drive J&J towards its goal of achieving $50 billion in annual oncology revenue by 2030.
- Market Outlook: The global antibody-drug conjugate market is projected to reach $21 billion by 2030 and $35 billion by 2035, meaning that the more effective J&J's ADC portfolio becomes, the more secure its market share and revenue targets will be.
See More
Johnson & Johnson Invests Over $1 Billion in Florida
- Significant Investment: Johnson & Johnson has announced an investment exceeding $1 billion in Jacksonville, Florida, aimed at enhancing its U.S.-based manufacturing, packaging, and distribution capabilities, highlighting the company's commitment to domestic production.
- Strategic Initiative: This investment is part of Johnson & Johnson's previously announced $55 billion U.S. investment plan, which encompasses manufacturing, research and development, and technology through early 2029, demonstrating the company's confidence in future growth.
- Facility Development: The new state-of-the-art distribution facility will incorporate advanced manufacturing and packaging technologies to expand capacity and meet the growing demand for ACUVUE-brand contact lenses, thereby enhancing market competitiveness.
- Market Reaction: In pre-market trading on the NYSE, Johnson & Johnson shares fell by 0.72% to $239.12, reflecting a cautious market response to the investment announcement.
See More
Johnson & Johnson Invests Over $1 Billion in Florida
- Massive Investment: Johnson & Johnson has announced an investment of over $1 billion in Jacksonville, Florida, aimed at scaling its U.S. Vision operations in manufacturing, packaging, and distribution to meet the needs of over 40 million patients, thereby reinforcing its leadership in eye health solutions.
- Significant Economic Impact: This investment is part of the company's ongoing $55 billion commitment to U.S. manufacturing, research, and technology, expected to enhance its $6 billion annual economic impact in Florida while providing more opportunities for its 3,500 Jacksonville employees, thus boosting the local economy.
- Advanced Technology Implementation: The new state-of-the-art distribution facility will integrate advanced manufacturing and packaging technologies to increase capacity and meet the growing demand for ACUVUE® brand contact lenses, ensuring continuous innovation in high-quality eye health solutions.
- Long-term Strategic Vision: CEO Joaquin Duato emphasized that this investment reflects confidence in advanced manufacturing in the U.S. and will enhance the resilience of the company's supply chain, helping more people see better and live better, showcasing Johnson & Johnson's long-term commitment to global eye health.
See More
Paths to Achieving $3,000 Monthly in Dividends
- Conservative Investment Path: To achieve $3,000 monthly in dividends at a 3.5% yield, approximately $1,028,571 must be invested, relying on dividend aristocrats and broad dividend-growth funds; despite Johnson & Johnson's current yield of only 2.3%, its 64 consecutive years of dividend growth indicate stability.
- Moderate Path Selection: At a 6% yield, the required capital drops to $600,000, primarily depending on net-lease REITs and high-yield consumer goods; although dividend growth tends to be slower, it provides relatively stable cash flow.
- Aggressive Path Risks: With a 10% yield, an investment of $360,000 can yield $3,000 monthly, but such investments often come with the risk of capital return, and dividends may be cut during economic downturns, necessitating careful selection.
- Growth Advantage Analysis: While high-yield investments offer more income in the short term, sustained dividend growth can significantly enhance income; a 3.5% portfolio could increase annual income from $35,000 to $70,000 over a decade, showcasing the power of compounding.
See More
Goldman Sachs Identifies High-Potential Stocks
- BrightSpring Health Services: Goldman Sachs initiated coverage with a buy rating and a $71 price target, highlighting its differentiated offerings in elder care that are expected to drive growth, with shares up 67% in 2026.
- Samsara Growth Potential: Analysts at Goldman Sachs view Samsara as one of the most defensible growth assets in software, anticipating improved profit margins, with shares rising 18% over the past month, recommending investors buy on any weakness.
- Ulta Beauty Market Share: Goldman Sachs believes Ulta is well-positioned to gain market share despite a 23% decline in stock this year, citing strong performance and share repurchase plans, with a target price of $652 indicating significant upside.
- Nvidia Investment Confidence: Goldman Sachs reiterated its buy rating on Nvidia, asserting that improved capital allocation will boost investor confidence, with growth expected to continue into 2027, with estimates over 30% above market expectations.
See More
TALVEY and DARZALEX Combination Therapy Significantly Improves Outcomes in Multiple Myeloma Patients
- Clinical Trial Results: Johnson & Johnson's MonumenTAL-3 study demonstrates that the combination of TALVEY and DARZALEX significantly reduces the risk of disease progression or death by 72% in patients with relapsed/refractory multiple myeloma, highlighting the efficacy of this regimen.
- Survival Rate Improvement: At 24 months, the progression-free survival rate for the TALVEY and DARZALEX combination reaches 81.3%, compared to only 51.2% for standard treatment, indicating the potential of this new therapy in earlier lines of treatment.
- Safety Analysis: While the side effects of the TALVEY and DARZALEX combination align with the known safety profiles of each monotherapy, the Tal-DP group shows a significantly lower risk of severe infections compared to standard treatment, indicating better tolerability.
- Market Outlook: Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for the TALVEY and DARZALEX combination therapy, which is expected to accelerate the market introduction of this treatment and further solidify its leadership position in the multiple myeloma treatment landscape.
See More
Johnson & Johnson Acquires Firefly Bio to Boost Cancer Drug Development
- Oncology Market Potential: Precedence Research indicates that the global oncology market is currently valued at nearly $280 billion and is projected to reach $700 billion by 2035, presenting significant growth opportunities for Johnson & Johnson.
- Acquisition Strategy: Johnson & Johnson's recent $1 billion acquisition of Firefly Bio aims to leverage its unique Firelink degrader antibody conjugate platform, focusing on treating KRAS tumors, thereby enhancing its competitive edge in cancer therapeutics.
- Technological Innovation: The Firelink platform enhances the efficacy of antibody-drug conjugates by targeting specific proteins on tumor cells, which is expected to drive J&J towards its goal of achieving $50 billion in annual oncology revenue by 2030.
- Market Outlook: The global antibody-drug conjugate market is projected to reach $21 billion by 2030 and $35 billion by 2035, meaning that the more effective J&J's ADC portfolio becomes, the more secure its market share and revenue targets will be.
See More
Johnson & Johnson Invests Over $1 Billion in Florida
- Significant Investment: Johnson & Johnson has announced an investment exceeding $1 billion in Jacksonville, Florida, aimed at enhancing its U.S.-based manufacturing, packaging, and distribution capabilities, highlighting the company's commitment to domestic production.
- Strategic Initiative: This investment is part of Johnson & Johnson's previously announced $55 billion U.S. investment plan, which encompasses manufacturing, research and development, and technology through early 2029, demonstrating the company's confidence in future growth.
- Facility Development: The new state-of-the-art distribution facility will incorporate advanced manufacturing and packaging technologies to expand capacity and meet the growing demand for ACUVUE-brand contact lenses, thereby enhancing market competitiveness.
- Market Reaction: In pre-market trading on the NYSE, Johnson & Johnson shares fell by 0.72% to $239.12, reflecting a cautious market response to the investment announcement.
See More
Johnson & Johnson Invests Over $1 Billion in Florida
- Massive Investment: Johnson & Johnson has announced an investment of over $1 billion in Jacksonville, Florida, aimed at scaling its U.S. Vision operations in manufacturing, packaging, and distribution to meet the needs of over 40 million patients, thereby reinforcing its leadership in eye health solutions.
- Significant Economic Impact: This investment is part of the company's ongoing $55 billion commitment to U.S. manufacturing, research, and technology, expected to enhance its $6 billion annual economic impact in Florida while providing more opportunities for its 3,500 Jacksonville employees, thus boosting the local economy.
- Advanced Technology Implementation: The new state-of-the-art distribution facility will integrate advanced manufacturing and packaging technologies to increase capacity and meet the growing demand for ACUVUE® brand contact lenses, ensuring continuous innovation in high-quality eye health solutions.
- Long-term Strategic Vision: CEO Joaquin Duato emphasized that this investment reflects confidence in advanced manufacturing in the U.S. and will enhance the resilience of the company's supply chain, helping more people see better and live better, showcasing Johnson & Johnson's long-term commitment to global eye health.
See More
Paths to Achieving $3,000 Monthly in Dividends
- Conservative Investment Path: To achieve $3,000 monthly in dividends at a 3.5% yield, approximately $1,028,571 must be invested, relying on dividend aristocrats and broad dividend-growth funds; despite Johnson & Johnson's current yield of only 2.3%, its 64 consecutive years of dividend growth indicate stability.
- Moderate Path Selection: At a 6% yield, the required capital drops to $600,000, primarily depending on net-lease REITs and high-yield consumer goods; although dividend growth tends to be slower, it provides relatively stable cash flow.
- Aggressive Path Risks: With a 10% yield, an investment of $360,000 can yield $3,000 monthly, but such investments often come with the risk of capital return, and dividends may be cut during economic downturns, necessitating careful selection.
- Growth Advantage Analysis: While high-yield investments offer more income in the short term, sustained dividend growth can significantly enhance income; a 3.5% portfolio could increase annual income from $35,000 to $70,000 over a decade, showcasing the power of compounding.
See More
Goldman Sachs Identifies High-Potential Stocks
- BrightSpring Health Services: Goldman Sachs initiated coverage with a buy rating and a $71 price target, highlighting its differentiated offerings in elder care that are expected to drive growth, with shares up 67% in 2026.
- Samsara Growth Potential: Analysts at Goldman Sachs view Samsara as one of the most defensible growth assets in software, anticipating improved profit margins, with shares rising 18% over the past month, recommending investors buy on any weakness.
- Ulta Beauty Market Share: Goldman Sachs believes Ulta is well-positioned to gain market share despite a 23% decline in stock this year, citing strong performance and share repurchase plans, with a target price of $652 indicating significant upside.
- Nvidia Investment Confidence: Goldman Sachs reiterated its buy rating on Nvidia, asserting that improved capital allocation will boost investor confidence, with growth expected to continue into 2027, with estimates over 30% above market expectations.
See More
